BioAtla (NASDAQ:BCAB) Rating Lowered to Neutral at HC Wainwright

BioAtla (NASDAQ:BCAB) was downgraded by equities research analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a report released on Wednesday, MarketBeat Ratings reports.

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price objective on shares of BioAtla in a research report on Monday, September 16th.

BioAtla Trading Down 14.1 %

Shares of BCAB stock opened at $1.71 on Wednesday. The company has a market cap of $82.66 million, a PE ratio of -1.04 and a beta of 1.03. The company’s fifty day simple moving average is $1.92 and its 200-day simple moving average is $1.88. BioAtla has a 52 week low of $1.14 and a 52 week high of $4.02.

BioAtla (NASDAQ:BCAB) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.12. The company had revenue of $11.00 million during the quarter. During the same quarter in the previous year, the business earned ($0.70) earnings per share. Equities research analysts expect that BioAtla will post -1.52 EPS for the current fiscal year.

Hedge Funds Weigh In On BioAtla

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vontobel Holding Ltd. bought a new position in shares of BioAtla during the third quarter worth about $28,000. Ground Swell Capital LLC acquired a new position in shares of BioAtla in the 2nd quarter worth approximately $33,000. Valmark Advisers Inc. bought a new stake in shares of BioAtla in the 2nd quarter valued at approximately $34,000. Rinkey Investments bought a new stake in shares of BioAtla in the 2nd quarter valued at approximately $35,000. Finally, Chicago Partners Investment Group LLC acquired a new stake in shares of BioAtla during the 3rd quarter valued at approximately $44,000. 77.23% of the stock is currently owned by hedge funds and other institutional investors.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.